Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Mirum Pharmaceuticals (Nasdaq: MIRM) has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for Wednesday, January 15, 2025, at 9:45 a.m. PT.

The event will include both a presentation and a question-and-answer session, which will be accessible via webcast. Interested parties can access the live webcast through the Investors and Media section of Mirum's corporate website. A replay of the webcast will remain available for 30 days following the presentation.

Mirum Pharmaceuticals specializes in identifying, acquiring, developing, and commercializing novel therapies for debilitating rare and orphan diseases.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the 43^rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025 at 9:45 a.m. PT.

The presentation and question and answer session will be webcast live and can be accessed by visiting the Investors and Media section of Mirum’s corporate website. The replay of the webcast will be available for 30 days.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. CHENODAL has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).

Mirum's late-stage pipeline includes investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Chenodiol, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023. Mirum has submitted a new drug application with the FDA for the approval of chenodiol to treat CTX in the U.S. Lastly, Mirum is planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.

To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).

View source version on businesswire.com: https://www.businesswire.com/news/home/20250106531324/en/

Investor Contact:

Andrew McKibben

ir@mirumpharma.com

Media Contact:

Erin Murphy

media@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.

FAQ

When is Mirum Pharmaceuticals (MIRM) presenting at the J.P. Morgan Healthcare Conference 2025?

Mirum Pharmaceuticals will present at the conference on Wednesday, January 15, 2025, at 9:45 a.m. PT in San Francisco, CA.

How long will the MIRM J.P. Morgan Healthcare Conference webcast replay be available?

The webcast replay will be available for 30 days following the presentation.

Where can investors watch Mirum Pharmaceuticals' (MIRM) J.P. Morgan Healthcare Conference presentation?

Investors can access the live webcast through the Investors and Media section of Mirum's corporate website.

What type of diseases does Mirum Pharmaceuticals (MIRM) focus on treating?

Mirum Pharmaceuticals focuses on developing therapies for debilitating rare and orphan diseases.